rss
Br J Ophthalmol 2007;91:62-68 doi:10.1136/bjo.2006.096693
  • Clinical science
    • Extended reports

Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma

  1. A T Fung1,
  2. S E Reid2,
  3. M P Jones2,
  4. P R Healey3,
  5. P J McCluskey4,
  6. J C Craig2
  1. 1Sydney Eye Hospital, Sydney, New South Wales, Australia
  2. 2School of Public Health, University of Sydney, Camperdown, Sydney, New South Wales, Australia
  3. 3Department of Ophthalmology, Centre of Vision Research, Millennium Institute, University of Sydney, Westmead, New South Wales, Australia
  4. 4Department of Ophthalmology, South Western Sydney Clinical School, University of New South Wales, Liverpool, New South Wales, Australia
  1. Correspondence to: A T Fung Sydney Eye Hospital, Macquane, Sydney, NSW 2000, Australia; adrianfungi{at}yahoo.com.au
  • Accepted 3 August 2006
  • Published Online First 6 September 2006

Abstract

Aim: To compare the efficacy and tolerability of latanoprost versus brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma.

Method: Systematic review of randomised controlled trials comparing latanoprost and brimondine, identified by searches including Medline, Embase and Cochrane Controlled Trials Register. Two reviewers independently assessed trials for eligibility and quality and extracted data. Data were synthesised (random effects model) and expressed as the absolute mean intraocular pressure (IOP) reduction difference from baseline to end point for efficacy and relative risk for adverse events. Subgroup analysis and regression were used to explore heterogeneity according to patient characteristics, trial design and quality.

Results: 15 publications reporting on 14 trials (1784 participants) were included for meta-analysis. IOP reduction favoured latanoprost (weighted mean difference (WMD) = 1.10 mm Hg (95% confidence interval (CI) 0.57 to 1.63)). Significant heterogeneity was present (χ213 = 38.29, p = 0.001, I2 = 66.0%). Subgroup analysis showed greater WMD for studies where data were analysed from end points >6 months duration, cross-over design, open-angle glaucoma or ocular hypertension and monotherapy. Multiple regression showed no significant association of WMD with trial duration (t9 = 1.92, p = 0.09), trial design (t9 = 1.79, p = 0.11), trial quality (t9 = −0.46, p = 0.66), or monotherapy or adjunctive therapy (t9 = −2.14, p = 0.06). Fatigue was less commonly associated with latanoprost (RR = 0.27, 95% CI 0.08 to 0.88). Publication bias was not evident on visual inspection of a funnel plot.

Conclusion: Latanoprost is more effective than brimonidine as monotherapy in lowering IOP. Brimonidine is associated with a higher rate of fatigue.

Footnotes

  • Published Online First 6 September 2006

  • Competing interests: None.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. web only appendices
  5. All versions of this article:
    1. bjo.2006.096693v1
    2. 91/1/62 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.